6.1 Section 8(6) of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires clinical commissioning groups, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this evaluation within 3 months of its date of publication.
6.2 The Welsh Ministers have issued directions to the NHS in Wales on implementing NICE highly specialised technologies guidance. When a NICE highly specialised technologies guidance recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 2 months of the first publication of the final evaluation determination.
6.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraph above. This means that, if a patient has hypophosphatasia and the doctor responsible for their care thinks that asfotase alfa is the right treatment, it should be available for use, in line with NICE's recommendations.
6.4 The company has proposed that asfotase alfa will be available to the NHS under commercial terms agreed with NHS England. The nature of these terms are commercial in confidence. It is the responsibility of the company to communicate details of the discount to the relevant NHS organisations. Any enquiries from NHS organisations about the commercial terms should be directed to GlobalGovernmentAffairs@Alexion.com.